艾迪注射液联合化疗治疗卵巢癌的疗效及安全性Meta分析  

Meta analysis of the effectiveness and safety of ovarian cancer treated with aidi injection and chemotherapy

作　　者：邱楠 陈小凤[1] 艾长江 张宏艳 李晓菲[1] 肖静[2] QIU Nan;CHEN Xiao-feng;AI Chang-jiang;ZHANG Hong-yan;LI Xiao-fei;XIAO Jing(Second Clinical Medicine School,Guangzhou University of Traditional Chinese Medicine,Guangdong Guangzhou 510000;Department of Gynecology,Guangdong Chinese Medicine Hospital,Guangzhou Guangdong 510000)

机构地区：[1]广州中医药大学第二临床医学院,广东广州510000 [2]广东省中医院妇科,广东广州510000

出　　处：《世界中西医结合杂志》2019年第4期467-472,480,共7页World Journal of Integrated Traditional and Western Medicine

基　　金：国家自然科学基金面上项目;国家自然科学基金管理局(E2KBC111143K22)

摘　　要：目的通过Meta分析评价艾迪注射液联合化疗治疗卵巢癌的疗效及安全性。方法检索中国期刊全文数据库(CNKI)、万方数据库、维普数据库(VIP)、中国生物医学文摘数据库(CBM)、Pub Med、Embase数据库及Cochrane library中关于艾迪注射液联合化疗治疗卵巢癌的随机对照试验(RCT),提取资料并进行质量评价,采用Rev Man 5. 3软件进行Meta分析。结果本研究共纳入21个RCT,共1323例卵巢癌患者。Meta分析结果显示:在常规化疗方案上联合艾迪注射液较单独使用化疗治疗卵巢癌有更高的缓解率[OR=2. 38,95%CI(1. 88,3. 01),P <0. 000 01],卵巢癌患者生活质量也有所提高[OR=3. 85,95%CI(2. 92,5. 09),P <0. 000 01],此外化疗期间的不良反应发生率也有所降低,如III度以上白细胞下降发生率[RR=0. 30,95%CI(0. 19,047)]、Ⅲ度以上血小板下降发生率[RR=0. 36,95%CI(0. 23,0. 54),P <0. 000 01]及Ⅲ度以上胃肠道反应发生率[RR=0. 21,95%CI(0. 11,0. 42),P <0. 000 01]。结论艾迪注射液联合化疗可以提高卵巢癌患者的缓解率,改善患者的生活质量,减少化疗期间的不良反应的发生。Objective To evaluate the effectiveness and safety of ovarian cancer treated with aidi injection and chemotherapy with meta analysis.Methods The randomized controlled trials(RTCs)of ovarian cancer treated with aidi injection and chemotherapy were retrieved from CNKI,Wanfang,VIP,CBM,Pubmed and Embase databases as well as Cochrane library.The data were extracted for quality assessment.RevMan 5.3 software was used for Meta analysis.Results A total of 21 RCTs were collected with 1323 patients of ovarian cancer.Meta analysis results indicated that on the base of the conventional chemotherapy,aidi injection was combined and achieved the higher remission rate compared with single use of chemotherapy[ OR=2.38,95% CI(1.88,3.01),P<0.000 01 ].The life quality of ovarian cancer patients was improved[ OR=3.85,95%CI(2.92,5.09),P <0.000 01].Moreover,during chemotherapy,the incidence of adverse reaction was reduced,such as the incidence of the reduction of white blood cells for the grade 3 or more than 3[ RR=0.30,95%CI (0.19,047)],the incidence of the reduction of blood platelet[ RR=0.36,95%CI(0.23,0.54),P <0.000 01]for the grade 3 or more than 3 and the incidence gastrointestinal reaction for the grade 3 or more than 3[ RR=0.21,95% CI(0.11,0.42),P <0.000 01].Conclusion The combined treatment of aidi injection and chemotherapy improves the remission rate and life quality and reduces the incidence of toxic side reaction during chemotherapy in the patients with ovarian cancer.

关 键 词：艾迪注射液 联合化疗 卵巢癌 META分析 

分 类 号：R737.31[医药卫生—肿瘤]